Smital Shah - Net Worth and Insider Trading

Smital Shah Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Smital Shah owns 2 companies in total, including Pliant Therapeutics Inc (PLRX) , and Graphite Bio Inc (GRPH) .

Click here to see the complete history of Smital Shah’s form 4 insider trades.

Insider Ownership Summary of Smital Shah

Ticker	Comapny	Transaction Date	Type of Owner
PLRX	Pliant Therapeutics Inc	2020-06-02	director
GRPH	Graphite Bio Inc	2021-06-24	director

Smital Shah Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Smital Shah Ownership Network

Ownership Network List of Smital Shah

No Data

Ownership Network Relation of Smital Shah

Smital Shah Owned Company Details

What does Pliant Therapeutics Inc do?

Who are the key executives at Pliant Therapeutics Inc?

Smital Shah is the director of Pliant Therapeutics Inc. Other key executives at Pliant Therapeutics Inc include Chief Business Officer Hans Hull , Chief Medical Officer Eric Lefebvre , and Chief Financial Officer Keith Lamont Cummings .

Pliant Therapeutics Inc (PLRX) Insider Trades Summary

Over the past 18 months, Smital Shah made no insider transaction in Pliant Therapeutics Inc (PLRX). Other recent insider transactions involving Pliant Therapeutics Inc (PLRX) include a net sale of 72,542 shares made by Hans Hull , a net sale of 30,386 shares made by Mike Ouimette , and a net sale of 134,581 shares made by Bernard Coulie .

In summary, during the past 3 months, insiders sold 0 shares of Pliant Therapeutics Inc (PLRX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 322,907 shares of Pliant Therapeutics Inc (PLRX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 322,907 shares.

Pliant Therapeutics Inc (PLRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Pliant Therapeutics Inc Insider Transactions

No Available Data

Smital Shah Mailing Address

Above is the net worth, insider trading, and ownership report for Smital Shah. You might contact Smital Shah via mailing address: C/o Pliant Therapeutics, Inc., 260 Littlefield Avenue, South San Francisco Ca 94080.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.